Searched for
ILUMYA SUN PHARMA
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...- Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...
- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Sun Pharma’s Ilumya expansion bid gets USFDA nod for reviewSun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for t...
- Sun Pharma launches Ilumya for psoriasis treatment in IndiaSun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....
- Sun Pharma brings global psoriasis drug ILUMYA to Indian marketSun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This nov...
- Sun Pharma shares slip 3% after BofA downgrade on premium valuationsBank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower speciality exec...
- Sun Pharma plans in-licensing, buyouts to expand speciality businessSpeciality drugs refer to high cost, high complexity medicines, including biologicals, for the treatment of complex or rare conditions. The...
- Sun Pharma arm launches plaque psoriasis treatment drug in JapanIn a regulatory filing, Sun Pharmaceutical Industries said its "wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection...
- Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA regionUnder the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA...
- Sun Pharma ex-employee alleges US Law violation, discriminationSandra Hagenbrock, who was national account director at Sun in the US and employed there from February 2016 to July 2019, alleged the compa...
- Sun Pharma's Q1 nos: One-off boost likely from US suppliesCentrum Broking expects Sun Pharma's India sales to grow at 7 per cent for the quarter.
- Goldman downgrades Sun Pharma to ‘sell’, also cuts its target priceThe downgrade led to the stock ending down 3 per cent at Rs 389.80 on Tuesday.
- Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Sun Pharma climbs over 3% after USFDA drug nodThe company informed stock exchanges about the USFDA nod after market hours of Wednesday.
- Tildra approval to give sentimental push to Sun PharmaThe drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...
- Sun Pharma gets USFDA nod for plaque psoriasis drugThe FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.
Load More
